Fallopian tube carcinoma Journal Article

Authors: Stasenko, M.; Fillipova, O.; Tew, W. P.
Article Title: Fallopian tube carcinoma
Abstract: Primary fallopian tube carcinoma is a rare and difficult to cure disease. It is often grouped under the epithelial ovarian cancer umbrella, together with primary ovarian and peritoneal carcinomas. More recent evidence has suggested that epithelial ovarian cancers originate from a fallopian tube precursor. The mainstay of treatment is surgical cytoreduction and platinum-based chemotherapy. There is much debate over the best timing for surgery and the best approach to delivering the chemotherapy: traditional intravenous once every 3 weeks regimen, versus intraperitoneal, versus dose-dense intravenous regimens. Although these debates continue, novel targeted therapies, including bevacizumab and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, have emerged. PARP inhibitors are particularly efficacious in patients with BRCA1/2 gene mutations, and their use has been shown to prolong patient survival. This article reviews the pathologic etiology; describes the heredity, treatment challenges, and controversies; and summarizes novel therapies in primary fallopian tube carcinoma. (C) 2019 by American Society of Clinical Oncology
Keywords: chemotherapy; breast; maintenance therapy; neoadjuvant chemotherapy; serous carcinoma; hereditary; phase-iii trial; intraperitoneal; epithelial ovarian; open-label; advanced ovarian-cancer; gynecologic-oncology
Journal Title: Journal of Oncology Practice
Volume: 15
Issue: 7
ISSN: 1554-7477
Publisher: American Society of Clinical Oncology  
Date Published: 2019-07-01
Start Page: 375
End Page: 382
Language: English
ACCESSION: WOS:000475450100007
DOI: 10.1200/jop.18.00662
PUBMED: 31283415
Notes: Author Olga Filippova's last name is misspelled on the original publication -- Source: Wos
Altmetric Score
MSK Authors
  1. William P Tew
    131 Tew